ArticleNanoscale advances2023
HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex.
Article in Nanoscale advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy.Precision radiation oncology · 2026Review
- Boron Neutron Capture Therapy for High-Grade CNS Tumors: Mechanisms, Carriers, and Clinical Progress: A Narrative Review.International journal of molecular sciences · 2026Review
- Nanobiomaterial-enabled boron delivery systems and innovative strategies for revolutionizing BNCT.Theranostics · 2026Review
- Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges.Biomaterials research · 2025Review
- Utilization of dual catalysts for high-yield boron nitride nanotube synthesis via chemical vapor deposition.Turkish journal of chemistry · 2025Article
- Review
- Recent progress of nano-drugs in neutron capture therapy.Theranostics · 2024Review
- Principles of Biocompatible Nanotube Design for High-Performance Biomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.